Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen

Chugai President and CEO Osamu Okuda Chugai Pharmaceutical’s sales and profits for the fiscal year ended December 2023 contracted by two digits over the year due to a smaller supply of the COVID-19 treatment Ronapreve (casirivimab/imdevimab) to the government as...read more